MARKET

VOR

VOR

Vor Biopharma Inc.
NASDAQ
18.09
+0.75
+4.33%
After Hours: 18.45 +0.36 +1.99% 18:53 07/17 EDT
OPEN
17.11
PREV CLOSE
17.34
HIGH
18.24
LOW
16.67
VOLUME
999.02K
TURNOVER
--
52 WEEK HIGH
53.20
52 WEEK LOW
6.50
MARKET CAP
980.22M
P/E (TTM)
-0.0617
1D
5D
1M
3M
1Y
5Y
1D
Can Vor Biopharma’s (VOR) New Board Appointment Reshape Its Late-Stage Commercialization Strategy?
Simply Wall St · 1d ago
Weekly Report: what happened at VOR last week (0706-0710)?
Weekly Report · 5d ago
Vor Biopharma director David Zaccardelli files initial beneficial ownership statement
PUBT · 07/09 20:01
Vor Biopharma Adds Industry Veteran David Zaccardelli to Board
TipRanks · 07/07 20:31
*Vor Biopharma: Andrew Levin Has Stepped Down From the Board
Dow Jones · 07/07 20:03
Vor Bio appoints former Verona Pharma CEO David Zaccardelli to board
PUBT · 07/07 20:01
VOR BIO APPOINTS DAVID ZACCARDELLI TO BOARD OF DIRECTORS
Reuters · 07/07 20:01
Press Release: Vor Bio Appoints David Zaccardelli to Board of Directors
Dow Jones · 07/07 20:01
More
About VOR
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.

Webull offers Vor Biopharma Inc stock information, including NASDAQ: VOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VOR stock methods without spending real money on the virtual paper trading platform.